Clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor and prognostic analysis
WU Wan-Shui1, LIU Jing-Jing1, SUN Yan-Ling1, REN Si-Qi1, QIU Xiao-Guang2, DU Shu-Xu1, LI Chun-De3, SUN Li-Ming1
Department of Pediatrics, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing 100038, China
Abstract：Objective To study the clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor (cPNET), as well as the risks factors for poor prognosis. Methods A retrospective analysis was performed for the clinical data of 42 children who were diagnosed with cPNET from June 2012 to September 2018. Results The 42 children had a median overall survival (OS) time of 2.0 years and a median event-free survival (EFS) time of 1.3 years; the 1-, 3-, and 5-year OS rates were 76.2%±6.6%, 41.4%±8.7%, 37.3%±8.8% respectively, and the 1-, 3-, and 5-year EFS rates were 64.3%±7.4%, 32.7%±8.0%, 28.0%±8.1% respectively. The univariate analysis showed that there were significant differences in the OS and EFS rates among the children with different patterns of surgical resection, chemotherapy cycles, and risk grades (P < 0.05), and there was also a significant difference in the OS rate between the children receiving radiotherapy and those not receiving radiotherapy (P < 0.05). The multivariate Cox regression analysis showed that chemotherapy cycles and risk grade were independent influencing factors for EFS and OS rates (P < 0.05). The EFS and OS rates increased with the increase in chemotherapy cycles and the reduction in risk grade. Conclusions Multimodality therapy with surgery, chemotherapy, and radiotherapy is an effective method for the treatment of cPNET in children. Early diagnosis and treatment and adherence to chemotherapy for as long as possible may improve EFS and OS rates.
WU Wan-Shui,LIU Jing-Jing,SUN Yan-Ling et al. Clinical effect of surgery combined with chemotherapy and radiotherapy in children with central primitive neuroectodermal tumor and prognostic analysis[J]. CJCP, 2020, 22(6): 589-594.
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109.
[2]
Chintagumpala M, Hassall T, Palmer S, et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET[J]. Neuro Oncol, 2009, 11(1):33-40.
[3]
Gill P, Litzow M, Buckner J, et al. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system[J]. Cancer, 2008, 112(8):1805-1811.
[4]
Chang CH, Housepian EM, Herbert JC Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas[J]. Radiology, 1969, 93(6):1351-1359.
[5]
Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone[J]. N Engl J Med, 2005, 352(10):978-986.
[6]
Sin-Chan P, Li BK, Ho B, et al. Molecular classification and management of rare pediatric embryonal brain tumors[J]. Curr Oncol Rep, 2018, 20(9):69.
[7]
Lester RA, Brown LC, Eckel LJ, et al. Clinical outcomes of children and adults with central nervous system primitive neuroectodermal tumor[J]. J Neurooncol, 2014, 120(2):371-379.
[8]
Stensvold E, Myklebust TÅ, Cappelen J, et al. Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013:unexplainable regional differences in survival[J]. Pediatr Blood Cancer, 2019, 66(10):e27910.
[9]
Kirkman MA, Hayward R, Phipps K, et al. Outcomes in children with central nervous system tumors disseminated at presentation:a large single-center experience[J]. Childs Nerv Syst, 2018, 34(11):2259-2267.
[10]
de Rojas T, Bautista F, Flores M, et al. Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain:room for improvement in standards of care[J]. J Neurooncol, 2018, 137(1):205-213.
[11]
Gerber NU, von Hoff K, Resch A, et al. Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy[J]. Int J Radiat Oncol Biol Phys, 2014, 89(4):863-871.
[12]
Friedrich C, Warmuth-Metz M, von Bueren AO, et al. Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT trials:clinical findings of a rare disease[J]. J Neurosurg Pediatr, 2015, 15(3):227-235.
[13]
Timmermann B, Kortmann RD, Kühl J, et al. Role of radiotherapy in supratentorial primitive neuroectodermal tumor in young children:results of the German HIT-SKK87 and HIT-SKK92 trials[J]. J Clin Oncol, 2006, 24(10):1554-1560.
Garcia-Moure M, Martinez-Velez N, Gonzalez-Huarriz M, et al. The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models[J]. Sci Rep, 2019, 9(1):14368.
[16]
Carceller F, Bautista F, Jiménez I, et al. Outcome of children and adolescents with central nervous system tumors in phase I trials[J]. J Neurooncol, 2018, 137(1):83-92.
[17]
Carceller F, Bautista FJ, Jiménez I, et al. Prognostic factors of overall survival in children and adolescents enrolled in dose-finding trials in Europe:an innovative therapies for children with cancer study[J]. Eur J Cancer, 2016, 67:130-140.
[18]
Ma J, Ma S, Yang J, et al. Primary spinal primitive neuroectodermal tumor:a single center series with literature review[J]. J Spinal Cord Med, 2018. DOI:10.1080/10790268.2018.1547862. Online ahead of print.
